Related Experiment Video
Updated: Jul 30, 2025

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation
Giovanni Cimmino1, Saverio Muscoli2, Salvatore De Rosa3
1Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples.
Insights
Atherosclerosis, a major cause of cardiovascular disease, involves inflammation and immunity. Emerging research highlights the gut microbiome
Area of Science:
- Cardiovascular Science
- Immunology
- Microbiology
Background:
- Atherosclerosis underlies many cardiovascular, cerebrovascular, and peripheral artery diseases.
- The roles of immunity and inflammation in atherosclerotic plaque formation, progression, and complication are well-established.
- Conventional risk factors initiate endothelial dysfunction, promoting a proatherosclerotic state.
Purpose of the Study:
- To review the pathophysiology of atherosclerotic lesions, including the impact of conventional and nonconventional risk factors.
- To explore the emerging role of the gut microbiome in atherosclerosis development and progression.
- To evaluate inflammation as a therapeutic target for managing atherosclerotic diseases.
Main Methods:
- Review of current scientific literature on atherosclerosis pathophysiology.
- Analysis of the interplay between conventional risk factors, inflammation, and immune responses.
- Investigation of the influence of gut dysbiosis and microbial metabolites on atherosclerotic lesion development.
Main Results:
- Atherosclerotic plaque progression involves lipid accumulation, immune cell activation, and cytokine release, leading to vulnerable lesions.
- Complicated plaques expose thrombogenic material, triggering coagulation and thrombus formation.
- Nonconventional risk factors, particularly gut dysbiosis, contribute to inflammation and disease progression.
Conclusions:
- Both conventional and nonconventional risk factors modulate atherosclerotic lesion inflammation.
- Targeting inflammation presents a promising strategy for improving the management of atherosclerosis-related diseases.
- The gut microbiome is an emerging factor influencing atherosclerotic disease pathogenesis.
Abstract:
Atherosclerosis is the anatomo-pathological substrate of most cardio, cerebro and vascular diseases such as acute and chronic coronary syndromes, stroke and peripheral artery diseases. The pathophysiology of atherosclerotic plaque and its complications are under continuous investigation. In the last 2 decades our understanding on the formation, progression and complication of the atherosclerotic lesion has greatly improved and the role of immunity and inflammation is now well documented and accepted. The conventional risk factors modulate endothelial function determining the switch to a proatherosclerotic phenotype. From this point, lipid accumulation with an imbalance from cholesterol influx and efflux, foam cells formation, T-cell activation, cytokines release and matrix-degrading enzymes production occur. Lesions with high inflammatory rate become vulnerable and prone to rupture. Once complicated, the intraplaque thrombogenic material, such as the tissue factor, is exposed to the flowing blood, thus inducing coagulation cascade activation, platelets aggregation and finally intravascular thrombus formation that leads to clinical manifestations of this disease. Nonconventional risk factors, such as gut microbiome, are emerging novel markers of atherosclerosis. Several data indicate that gut microbiota may play a causative role in formation, progression and complication of atherosclerotic lesions. The gut dysbiosis-related inflammation and gut microbiota-derived metabolites have been proposed as the main working hypothesis in contributing to disease formation and progression. The current evidence suggest that the conventional and nonconventional risk factors may modulate the degree of inflammation of the atherosclerotic lesion, thus influencing its final fate. Based on this hypothesis, targeting inflammation seems to be a promising approach to further improve our management of atherosclerotic-related diseases.
Related Concept Videos
Atherosclerosis I: Introduction
Coronary Artery Disease II: Pathophysiology
Inflammation
Peripheral Artery Disease I: Introduction
Coronary Artery Disease I: Introduction
Atherosclerosis III: Management

